Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591)

Market Cap	1.41B -89.9%
Revenue (ttm)	176.96M +171.6%
Net Income	-386.00M
EPS	-0.85
Shares Out	456.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,008,000
Open	3.310
Previous Close	3.275
Day's Range	3.085 - 3.355
52-Week Range	3.085 - 48.360
Beta	n/a
Analysts	Strong Buy
Price Target	20.69 (+570.67%)
Est. Earnings	Nov 25, 2026

About HKG:2591

Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company’s products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 214
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2591

Financial Performance

Financial numbers in CNY

Analyst Summary

According to 2 analysts, the average rating for 2591 stock is "Strong Buy." The 12-month stock price target is $20.69, which is an increase of 570.67% from the latest price.

Price Target

$20.69

(570.67% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error